[go: up one dir, main page]

WO2017187338A1 - Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents

Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2017187338A1
WO2017187338A1 PCT/IB2017/052372 IB2017052372W WO2017187338A1 WO 2017187338 A1 WO2017187338 A1 WO 2017187338A1 IB 2017052372 W IB2017052372 W IB 2017052372W WO 2017187338 A1 WO2017187338 A1 WO 2017187338A1
Authority
WO
WIPO (PCT)
Prior art keywords
complex
lumacaftor
recited
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/052372
Other languages
French (fr)
Other versions
WO2017187338A4 (en
Inventor
Richard Balázs Kárpáti
Betti SZABÓNÉ ORDASI
Orsolya Basa-Dénes
Erzsébet Réka ANGI
Tamás Jordán
László MOLNÁR
Hristos Glavinas
Zsolt ÖTVÖS
Genovéva FILIPCSEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tavanta Therapeutics Hungary Inc
Original Assignee
Druggability Technologies IP Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Technologies IP Holdco Ltd filed Critical Druggability Technologies IP Holdco Ltd
Priority to EP17731268.3A priority Critical patent/EP3448385A1/en
Priority to CA3021941A priority patent/CA3021941A1/en
Priority to AU2017256182A priority patent/AU2017256182A1/en
Priority to CN201780039665.5A priority patent/CN109475547A/en
Priority to JP2018555731A priority patent/JP2019514897A/en
Publication of WO2017187338A1 publication Critical patent/WO2017187338A1/en
Publication of WO2017187338A4 publication Critical patent/WO2017187338A4/en
Priority to IL262490A priority patent/IL262490A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention is directed to a stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Lumacaftor, or its salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and eliminate the food effect.
  • the invention also relates to methods of formulating and manufacturing complexes according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
  • Lumacaftor is one of the active ingredients in ORKAMBI® tablets, which has the following chemical name: 3-[6-( ⁇ [l-(2,2-difluoro-l,3-benzodioxol-5- yl)cyclopropyl]carbonyl ⁇ amino)-3-methylpyridin-2-yl]benzoic acid.
  • the molecular formula for lumacaftor is C 24 H 18 F 2 N 2 0 5 .
  • the molecular weight for Lumacaftor is 452.41.
  • the structural formula is:
  • Lumacaftor is a white to off-white powder that is practically insoluble in water mg/mL).
  • ORKAMBI® is available as a pink, oval-shaped, film-coated tablet for oral administration containing 200 mg of Lumacaftor and 125 mg of Ivacaftor.
  • Each ORKAMBI® tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor, and the following inactive ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose acetate succinate; magnesium stearate; povidone; and sodium lauryl sulfate.
  • the tablet film coat contains carmine, FD&C Blue #1, FD&C Blue #2, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
  • the printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
  • Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. ln-vitro studies have demonstrated that Lumacaftor acts directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport.
  • Lumacaftor Following multiple oral dose administrations of Lumacaftor, the exposure of Lumacaftor increased roughly proportionally with dose from 50 to 1000 mg qd. In subjects with cystic fibrosis (CF), the Lumacaftor C max and AUC also increases approximately proportional with the dose over the Lumacaftor 25 mg qd to 400 mg ql2h dose range. The exposure of Lumacaftor increased approximately 1.6-to 2.0-fold when given with fat containing food. The median (range) time of the maximum concentration (t ⁇ ) is approximately 4.0 (2.0, 9.0) hours in the fed state.
  • CF cystic fibrosis
  • Lumacaftor exposure was approximately 2 times higher and Ivacaftor exposure was approximately 3 times higher than when taken in a fasting state.
  • Lumacaftor Following multiple oral dose administration of Lumacaftor in combination with Ivacaftor, the exposure of Lumacaftor generally increased proportional to dose over the range of 200 mg every 24 hours to 400 mg every 12 hours.
  • the median (range) of Lumacaftor is approximately 4.0 hours (2.0; 9.0) in the fed state.
  • Lumacaftor is approximately 99% bound to plasma proteins, primarily to albumin. After oral administration of 200 mg every 24 hours for 28 days to patients with CF in a fed state, the mean (+SD) for apparent volumes of distribution was 86.0 (69.8) L. [0010] The half-life of Lumacaftor is approximately 26 hours in patients with CF. The typical apparent clearance, CL/F (CV), of Lumacaftor was estimated to be 2 38 L/hr (29.4%) for patients with CF.
  • Lumacaftor is not extensively metabolized in humans with the majority (51%) of Lumacaftor excreted unchanged in the feces. There was minimal elimination of Lumacaftor and its metabolites in urine (only 8.6% of total radioactivity was recovered in the urine with 0.18% as unchanged parent). ln-vitro and in vivo data indicate that Lumacaftor is mainly metabolized via oxidation and glucuronidation.
  • Lumacaftor has low aqueous solubility and high permeability assessed via the colorectal adenocarcinoma (Caco-2) cell system. Although pH-dependent solubility was observed, the Lumacaftor drug substance is practically insoluble in water and buffer solutions of pH 1.0 to pH 8.0. Therefore, Lumacaftor is suggested to be a BCS Class 2 (low solubility/high permeability) compound.
  • Lumacaftor is considered a BCS class II
  • the drug substance was jet-milled early in development to reduce the particle size and potentially improve bioavailability. Based on these studies a control on Lumacaftor particle size in the drug substance specification was established.
  • Lumacaftor alone and in combination which includes suspension, capsules and tablets. Comparative exposure of the different formulations of Lumacaftor was seen in single dose studies in healthy volunteers. Exposure of the suspension is lower than that seen for capsules and tablets. Early clinical studies were conducted with the co-administration of both Ivacaftor and Lumacaftor. A cross-over study (007) was conducted to evaluate the relative bioavailability of the fixed dose combination tablet as compared to the separate tablets.
  • the tablet and FDC appear to be bioequivalent, and the only parameter that did not meet standard bioequivalence criteria is the C max of Ivacaftor (GLSMR [90% CI] - 1.20 [1.09, 1.33]). However, for practical purposes, this is acceptable and the PK results from tablet formulation can be considered applicable to the FDC as well.
  • novel complex formulations of Lumacaftor or its salts or its derivatives thereof and complexation agents and pharmaceutically acceptable excipients were prepared. Novel complex formulations of the present invention are characterized by instantaneous redispersibility, increased apparent solubility, instantaneous dissolution, increased apparent permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.
  • a stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Lumacaftor, or a salt or derivative thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2- oxazoline), polyvinylpyrrolidone, , poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/ propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii.
  • said complex has a particle size is between 10 nm and 500 nm, and possesses one or more among the following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/mL; d) has a PAMPA permeability of at least 2xlCT 6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
  • the complex according to Point 6 wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA permeability of at least 2x10 "6 cm/ s in FaSSIF and FeSSIF biorelevant media.
  • said complexing agent is a copolymer of vinylpyrrolidone and vinylacetate.
  • the complex according to Point 1 comprising a) Lumacaftor; b) as complexation agent a copolymer of vinylpyrrolidone and vinylacetate; c) as an excipient sodium lauryl sulfate; wherein said complex is characterized by infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm 4 , 1021 cm 4 , 1165 cm 4 , 1231 cm , 1288 cm , 1369 cm , 1423 cm 4 , 1462 cm 4 , 1494 cm 4 , 1667 cm 4 and 1731 cm 4 ; and is characterized by Raman shifts at 553 cm 4 , 602 cm 4 , 635 cm 4 , 654 cm , 747 cm 4 , 841 cm 4 , 899 cm 4 , 934 cm 1 , 1002 cm 4 , 1021 cm 4 , 1117 cm , 1205 cm 4 , 1232 cm 4 , 1310 cm , 1352 cm
  • a complex according to either of Point 1 or Point 13 comprising a complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
  • a complex according to either of Point 1 or Point 15 comprising a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 50 weight % to about 95.0 weight % based on the total weight of the complex.
  • a process for the preparation of a stable complex according to Point 1 comprising the step of mixing a pharmaceutically acceptable solution containing Lumacaftor, and at least one complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lautyl sulfate.
  • a pharmaceutical composition comprising the stable complex according to Point 1 together with a pharmaceutically acceptable carrier.
  • composition according to Point 24, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
  • composition comprising the complex according to Point 26, wherein said composition comprises fast dissolving granules of the complex formulation according to Point 1.
  • composition comprising the complex according to Point 27, wherein said granules are suitable for the preparation of sachet dosage form.
  • CFTR mediated diseases are selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseud
  • a method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the complex according to Point 1 or the pharmaceutical composition according to Point 24.
  • 32. A stable complex comprising a) 5— 40% by weight of Lumacaftor, or its salt; b) 50— 90% by weight of a copolymer of vinylpyrrolidone and vinylacetate; and c) 0.01— 50 % by weight of sodium lauryl sulfate wherein said complex has a controlled particle size in the range between 10 nm and 500 nm; and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
  • 33. The complex according to Point 1, wherein said complex further comprises one or more additional active agents.
  • stable complexes comprising as active compound Lumacaftor, or salts or derivatives thereof; and at least one complexation agent.
  • said complex further comprises at least one pharmaceutically acceptable excipient.
  • complexing agents themselves or together with the pharmaceutically acceptable excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions.
  • the secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, ⁇ - ⁇ interactions, and hydrophobic interactions.
  • said complex has improved physicochemical characteristics and enhanced biological performance and comprises
  • Lumacaftor or a salt thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2- ethyl-2-oxazoline), polyvinylpyrrolidone, , poly(maleic acid/methyl vinyl ether),
  • complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2- ethyl-2-oxazoline), polyvinylpyrrolidone,
  • said complex has a particle size is between 10 nm and 500 nm, and possesses one or more among the following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/ mL; and d) has a PAMPA permeability of at least 2x10 "6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
  • said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate, polyethylene- glycols.
  • said complexation agent is copolymer of vinylpyrrolidone and vinyl acetate.
  • said copolymer of vinylpyrrolidone and vinyl acetate has a 60:40 weight ratio of vinylpyrrolidone:vinyl acetate monomers.
  • said pharmaceutically acceptable excipient is chosen from sodium lauryl sulfate (SDS), dioctyl sodium sulfosuccinate (DSS), cetylpyridinium chloride (CPC), sodium acetate (NaOAC), sodium deoxycholate (SDC), meglumine, D-mannitol, Kollicoat-IR, citric acid and lactose.
  • said pharmaceutically acceptable excipient is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
  • said pharmaceutically acceptable excipient is sodium lauryl sulfate.
  • compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
  • said complexes have particle size between 10 nm and 500 nm. [0031] In an embodiment, said particle size is between 10 nm and 250 nm.
  • said complex has increased dissolution rate compared to crystalline Lumacaftor.
  • said complex is stable in solid form and in colloid solution and/or dispersion.
  • said complex has apparent solubility in water is at least 1 mg/ mL.
  • said complex exhibits X-ray amorphous character in the solid form.
  • said complex has a PAMPA permeability of at least 2x10 "6 cm/ s when dispersed in FaSSIF media, which does not decrease in time at least for 12 months.
  • the variability of exposure of the complex is significantly reduced compared to the commercially available form (ORKAMBI®).
  • said complex has no observable food effect in-vitro, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
  • said complex or its pharmaceutical composition according to the invention characterized by Raman spectrum shown in Figure 7 and ATR spectrum shown in Figure 8.
  • said complex is characterized by Raman shifts at 553 cm 4 , 602 cm 4 , 635 cm , 654 cm 4 , 747 cm 1 , 841 cm , 899 cm 4 , 934 cm 4 , 1002 cm 4 , 1021 cm , 1117 cm , 1205 cm 4 , 1232 cm 4 , 1310 cm 4 , 1352 cm , 1372 cm 4 , 1428 cm 4 , 1444 cm , 1497 cm 4 , 1592 cm 4 , 1609 cm , 1677 cm 4 and 1737 cm 4 .
  • said complex is characterized by infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm , 1021 cm 4 , 1165 cm , 1231 cm , 1288 cm , 1369 cm 1 , 1423 cm 1 , 1462 cm 1 , 1494 cm 1 , 1667 cm 1 and 1731 cm .
  • ATR infrared
  • said complex comprises a) Lumacaftor; or a combination of active compounds including Lumacaftor; b) a complexing agent which is a copolymer of vinylpyrrolidone and vinyl acetate; and c) sodium lauryl sulfate as an excipient.
  • said complex comprises complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
  • said complex comprises complexation agent which is copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate comprise 50 weight % to about 95 weight % of the total weight of the complex.
  • a stable complex comprising i. 5— 40% by weight of Lumacaftor, its salt, or derivatives thereof; ii. 50— 90% by weight of copolymer of vinylpyrrolidone and vinylacetate; iii. 0.01 - 30 % by weight of sodium lauryl sulfate.
  • a process for the preparation of a stable complex of Lumacaftor comprising the step of mixing a pharmaceutically acceptable solution containing the active agent and at least one complexing agent and optionally one or more pharmaceutically acceptable excipient with an aqueous solution containing optionally least one pharmaceutically acceptable excipient.
  • said complex is obtained via a mixing process.
  • said complex is obtained via a continuous flow mixing process.
  • said process is performed in a continuous flow instrument.
  • said continuous flow instrument is a microfluidic flow instrument.
  • said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
  • the pharmaceutically acceptable solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
  • said pharmaceutically acceptable solvent is methanol.
  • said pharmaceutically acceptable solution and said aqueous solution are miscible with each other.
  • said aqueous solution comprises 0.1 to 99.9% weight of the final solution.
  • said aqueous solution comprises 50 to 90% weight of the final solution.
  • said aqueous solution comprises 50 to 80% weight of the final solution.
  • said aqueous solution comprises 50 to 70% weight of the final solution.
  • said aqueous solution comprises 50 to 60% weight of the final solution. [0060] In an embodiment, said aqueous solution comprises 45 to 55% weight of the final solution.
  • said aqueous solution comprises 50 % weight of the final solution.
  • said aqueous solution comprises 35 to 45 % weight of the final solution.
  • said aqueous solution comprises 25 to 35 % weight of the final solution.
  • said aqueous solution comprises 15 to 25 % weight of the final solution.
  • said aqueous solution comprises 5 to 15 % weight of the final solution.
  • a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
  • said pharmaceutical composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
  • said pharmaceutical compositions are suitable for oral administration.
  • said pharmaceutical composition comprises fast dissolving granules.
  • said granules are suitable for the preparation of sachet dosage form.
  • said complexes are for use in the manufacture of a medicament for the treatment of CFTR mediated diseases.
  • said complexes are used for the treatment of CFTR mediated diseases.
  • CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs,
  • a method of treatment of CFTR mediated diseases comprises administration of a therapeutically effective amount of complexes or pharmaceutical compositions as described herein.
  • a method for reducing the therapeutically effective dosage of Lumacaftor compared to commercially available ORKAMBI® comprises oral administration of a pharmaceutical composition as described herein.
  • said complexes further comprise one or more additional active agents.
  • said additional active agent is Ivacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
  • said complex comprises Lumacaftor; or a combination of active compounds including Lumacaftor; a complexing agent which is copolymers of vinylpyrrolidone and vinyl acetate and sodium lauryl sulfate as an excipient; said complexes characterized in that they possess at least one of the following properties: a) is instantaneously redispersible in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has apparent solubility in water of at least 1 mg/ mL; and d) has a PAMPA permeability of at least 2xl0 ⁇ 6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
  • said complex possesses at least two of the properties described in a)- d).
  • said complex possesses at least three of the properties described in a)- d).
  • novel complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and eliminate the food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
  • Lumacaftor is generally used for Lumacaftor, or its salts or its derivatives.
  • said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
  • polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (cop
  • said complexation agent is a copolymer of vinylpyrrolidone and vinyl acetate and said pharmaceutically acceptable excipient is sodium lauryl sulfate
  • a) is characterized by Raman shifts at 553 cm 4 , 602 cm 4 , 635 cm 4 , 654 cm 4 , 747 cm 4 , 841 cm 4 , 899 cm , 934 cm 4 , 1002 cm , 1021 cm 4 , 1117 cm , 1205 cm , 1232 cm , 1310 cm , 1352 cm 4 , 1372 cm , 1428 cm , 1444 cm 4 , 1497 cm , 1592 cm 4 , 1609 cm 4 , 1677 cm 1 and 1737 cm 4 ; and b) is characterized by infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm 4 , 1021 cm 4 , 1165 cm 4 , 1231 cm 4 , 1288 cm
  • ATR infrare
  • compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
  • active agents may include agents useful for the treatment of CFTR mediated diseases.
  • Another aspect of the invention is the complex formulations of the Lumacaftor with complexation agents and pharmaceutically acceptable excipients in which the complexation agents and pharmaceutically acceptable excipients preferably are associated or interacted with the Lumacaftor, such as the results of a mixing process or a continuous flow mixing process.
  • the structure of the complex Lumacaftor formulation is different from the core-shell type milled particle, precipitated encapsulated particles, micelles and solid dispersions.
  • the pharmaceutical composition of the invention can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination of (a), (b), and (c).
  • compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
  • the dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
  • Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders (sachet), and granules.
  • the complex formulation of Lumacaftor is admixed with at least one of the following: one or more inert excipients (or carriers): (a) fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, etythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide; (b) sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotam
  • the dosage form of the invention is a liquid dispersible granules in a sachet form.
  • said liquid dispersible granules comprise the complex formulation of Lumacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide.
  • pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol
  • said liquid dispersible granules comprise the complex formulation of Lumacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid.
  • pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin di
  • liquid dispersible granules comprising a) 25—95 % stable complex formulation of Lumacaftor of the present invention
  • said dispersion time is between 0.1 min and 10 min.
  • said dispersion time is between 0.1 min and 5 min.
  • said dispersion time is between 0.1 min and 3 min.
  • said dispersion time is between 0.1 min and 1 min.
  • Hausner-ratio of the said liquid dispersible granules of complex Lumacaftor formulations is less than 1.25, more preferably 1.00-1.18
  • Hausner-ratio of the said liquid dispersible granules of complex Lumacaftor formulations is between 1.00 and 1.18.
  • the particle size (D(90)) of said solid aggregates of complex Lumacaftor formulations is less than 2000 micrometers.
  • 60-99 % of the said solid aggregates of complex Lumacaftor formulations are in the size range of 160-1200 micrometers
  • said liquid is water, saliva, other physiologically or biologically acceptable fluid.
  • the dosage form is chosen from a tablet and a capsule.
  • Advantages of the complex Lumacaftor formulation of the invention include, but are not limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased apparent solubility and permeability compared to the conventional Lumacaftor formulation in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect, (5) good processability.
  • said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, improved permeability in fasted and fed state simulation, exhibits no observable food effect which deliver full absorption and the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form.
  • said complex possesses instantaneous redispersibility, has a
  • the complex Lumacaftor formulation of the present invention has increased apparent solubility and permeability.
  • the apparent solubility and permeability of the complex Lumacaftor formulation is at least 1 mg/mL and 2xl0 ⁇ 6 cm/s in FaSSIF and FeSSIF biorelevant media, respectively.
  • said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, and has a PAMPA permeability of at least 2x10 "6 cm/ s in FaSSIF and FeSSIF biorelevant media.
  • the complex Lumacaftor formulations of the present invention have an enhanced pharmacokinetic performance with improved solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.
  • Figure 1 shows redispersibility of complex Lumacaftor compositions in ultrapurified water.
  • Figure 2 shows redispersibility and PAMPA permeability of complex Lumacaftor compositions in purified water.
  • Figure 3 shows PAMPA permeability of complex Lumacaftor formulations containing vinylpyrrolidone and vinylacetate copolymer and sodium lauryl sulfate in different ratios.
  • Figure 4. shows optimization of production parameters.
  • Figure 5 shows Lumacaftor dissolution from crystalline Lumacaftor and complex Lumacaftor formulation.
  • Figure 6 shows PAMPA permeabilities of Lumacaftor formulations measured at different time points.
  • Figure 7. shows SEM photo of complex Lumacaftor formulation.
  • Figure 8 shows Raman spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Kollidon VA64 (E), SDS (F).
  • Figure 9 shows ATR spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Kollidon VA64 (E), SDS (F).
  • Figure 10 shows XRD diffractograms of crystalline Lumacaftor and complex Lumacaftor formulation.
  • Figurell. shows apparent solubility of Lumacaftor formulations.
  • Figurel2. shows PAMPA permeability of Lumacaftor formulations.
  • the receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1 % sodium dodecyl sulfate.
  • the assay was performed at room temperature; incubation time was 4 hours in ultrapurified water, FaSSIF and FeSSIF, respectively.
  • the concentration in the receiver compartment was determined by UV-VIS spectrophotometry (VWR UV-3100PC Scanning Spectrophotometer).
  • Copolymer of vinylpyrrolidone and vinylacetate was selected as complexing agents and sodium lauryl sulfate was selected as pharmaceutically acceptable excipient in order to prepare complex Lumacaftor formulations having improved material characteristics.
  • the ratio of the selected complexation agent and pharmaceutically acceptable excipient was optimized. Solid complexes of Lumacaftor were prepared by using different ratios of complexation agent and pharmaceutically acceptable excipient. PAMPA permeability measurements were used to select the best performing complex formulation ( Figure 3) . The optimal ratio of the copolymer of vinylpyrrolidone and vinylacetate : sodium lauryl sulfate: Lumacaftor (API) was found to be 9:1.2:2. Production of complex Lumacaftor formulations [00119] A solution mixture of Lumacaftor complex formulation was prepared by continuous flow mixing approach.
  • Solution 1 20 mL Solution 1 was prepared by dissolving 40 mg Lumacaftor and 180 mg copolymer of vinylpyrrolidone and vinylacetate in 20 mL methanol.
  • the prepared Solution 1 was mixed with Solution 2 containing 24 mg sodium lauryl sulfate in 80 mL water at 1:4 volume ratio in order to produce complex Lumacaftor formulation with different flow rates.
  • the solution mixture of the complex Lumacaftor formulation was produced at atmospheric pressure and ambient temperature. The appearance and the particle size of the produced colloid solution were monitored. Based on the physical appearance and particle size of the produced complex Lumacaftor formulation in colloid solution, the best composition was selected for further experiments (Figure 4).
  • the produced solution mixture was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump. Spray-drying was also applicable to produce solid powder from the solution mixture of complex Lumacaftor formulation.
  • a colloid solution of complex Lumacaftor formulation of the present invention was prepared by mixing process.
  • Solution 1 containing 200 mg Ivacaftor and 900 mg copolymer of vinylpyrrolidone and vinylacetate in 20 mL methanol was mixed with aqueous Solution 2 containing 120 mg sodium lauryl sulfate in 80 mL ultrapurified water at 1:4 volume ratio in order to produce complex Lumacaftor formulation.
  • the produced solution mixture was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump.
  • Spray-drying was also applicable to produce solid powder from the solution mixture of complex
  • Liquid dispersible granules comprising the complex Lumacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
  • [00122]Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Lumacaftor into compacts and breaking of the compacts into granules with appropriate mesh size.
  • the obtained granules can be mixed with pharmaceutically acceptable excipients.
  • Powder blend consists of the powder formulation of complex Lumacaftor and pharmaceutically acceptable excipients and prepared by mixing of powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
  • Wet granulation process covers the moisturizing of the powder formulations of complex Lumacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and mixing it with the powder formulations of complex Lumacaftor (indirect granulation).
  • the particle size of the granules can be controlled by physical impact before and after the drying step.
  • Liquid dispersible granules of complex Lumacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Lumacaftor powder blend using 0.5 ton load.
  • the powder blend comprised of the solid formulation of the complex of Lumacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents.
  • the height of the compact was found to be optimal between 0.8-1.0 mm.
  • the compacts were broken up by physical impact to form granulates.
  • the particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160- 800 micrometers particle size.
  • the Hausner-ratio of the granule was between 1.00 and 1.18 and the Carr's index was ⁇ 15.
  • the apparent solubility of complex Lumacaftor formulation of the present invention was measured by UV-VIS spectroscopy at room temperature.
  • the solid complex Lumacaftor formulations were dispersed in ultrapurified in 1, 10 and 20 mg/mL Lumacaftor equivalent concentration range.
  • the resulting solutions were filtered by 100 nm disposable syringe filter.
  • the Lumacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated.
  • the filtrate may contain Lumacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
  • the apparent solubility of complex Lumacaftor formulation of the present invention was 0.950, 9.839 and 14.913 mg/mL, when 1, 10 and 20 mg/mL Lumacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
  • the apparent solubility of unformulated crystalline Lumacaftor was found to be 0.032 mg/mL.
  • Solubility of complex Lumacaftor formula was 1 mg/mL. Comparative dissolution tests
  • PAMPA permeabilities of amorphous Lumacaftor, crystalline Lumacaftor and complex Lumacaftor formulation were measured and compared in simulated fasted state.
  • PAMPA permeability of amorphous Lumacaftor, crystalline Lumacaftor and complex Lumacaftor formulation was 1.1798xl0 ⁇ 6 cm/s, 0.53053xl0 ⁇ 6 cm/s and 3.9615x10 6 cm/ s, respectively.
  • PAMPA permeabilities of the solid complex Lumacaftor formulations were used to monitor the physical stability of the formulations. PAMPA permeability was measured in FaSSIF biorelevant media and after storage at different conditions. 1 month storage at RT or 40 °C 75% relative humidity showed no significant decrease in the measured PAMPA permeability ( Figure 6).
  • Complex Lumacaftor formulation of the present invention comprises spherical particles in the size range of less than 100 nm ( Figure 7).
  • Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic Raman shifts at 553 cm 4 , 654 cm 4 , 747 cm 4 , 841 cm 4 , 899 cm 4 , 1117 cm , 1205 cm , 1310 cm 4 , 1372 cm , 1428 cm 4 , 1677 cm 1 and 1737 cm .
  • Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm 4 , 1021 cm 4 , 1165 cm , 1231 cm 4 , 1288 cm , 1369 cm 4 , 1423 cm , 1462 cm , 1494 cm 4 , 1667 cm 1 and 1731 cm 4 shown in Figure 9.
  • ATR characteristic infrared
  • Crystalline Lumacaftor was ball milled in the absence of complexation agent (Kollidon VA64) and pharmaceutically acceptable excipient (SDS) and in the presence of them. Ball milling parameters were the following:
  • the vessel was washed out with 5 mL Milli-Q water.
  • the product was frozen on salted ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump.
  • the material and in-vitro properties of the resulted formulations were compared to the complex Lumacaftor formulation of the present invention.
  • PAMPA permeability of the formulations was measured in FaSSIF biorelevant media and compared.
  • PAMPA permeability of the complex Lumacaftor formulation was 4.651x10 6 cm/s, while it was 0.288xl0 ⁇ 6 cm/s for the ball milled crystalline Lumacaftor ( Figure 12).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulations of the present invention have improved dissolution and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.

Description

COMPLEXES OF LUMACAFTOR AND ITS SALTS AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FIELD OF THE INVENTION
[001] The invention is directed to a stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Lumacaftor, or its salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and eliminate the food effect. The invention also relates to methods of formulating and manufacturing complexes according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
BACKGROUND OF THE INVENTION
[002] Lumacaftor is one of the active ingredients in ORKAMBI® tablets, which has the following chemical name: 3-[6-({ [l-(2,2-difluoro-l,3-benzodioxol-5- yl)cyclopropyl]carbonyl} amino)-3-methylpyridin-2-yl]benzoic acid. The molecular formula for lumacaftor is C24H18F2N205. The molecular weight for Lumacaftor is 452.41. The structural formula is:
Figure imgf000003_0001
[003] Lumacaftor is a white to off-white powder that is practically insoluble in water mg/mL). [004] ORKAMBI® is available as a pink, oval-shaped, film-coated tablet for oral administration containing 200 mg of Lumacaftor and 125 mg of Ivacaftor. Each ORKAMBI® tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor, and the following inactive ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose acetate succinate; magnesium stearate; povidone; and sodium lauryl sulfate. The tablet film coat contains carmine, FD&C Blue #1, FD&C Blue #2, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
[005] Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. ln-vitro studies have demonstrated that Lumacaftor acts directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport.
[006] Following multiple oral dose administrations of Lumacaftor, the exposure of Lumacaftor increased roughly proportionally with dose from 50 to 1000 mg qd. In subjects with cystic fibrosis (CF), the Lumacaftor Cmax and AUC also increases approximately proportional with the dose over the Lumacaftor 25 mg qd to 400 mg ql2h dose range. The exposure of Lumacaftor increased approximately 1.6-to 2.0-fold when given with fat containing food. The median (range) time of the maximum concentration (t^) is approximately 4.0 (2.0, 9.0) hours in the fed state. [007] When a single dose of Lumacaftor and Ivacaftor was administered with fat-containing foods, Lumacaftor exposure was approximately 2 times higher and Ivacaftor exposure was approximately 3 times higher than when taken in a fasting state.
[008] Following multiple oral dose administration of Lumacaftor in combination with Ivacaftor, the exposure of Lumacaftor generally increased proportional to dose over the range of 200 mg every 24 hours to 400 mg every 12 hours. The median (range) of Lumacaftor is approximately 4.0 hours (2.0; 9.0) in the fed state.
[009] Lumacaftor is approximately 99% bound to plasma proteins, primarily to albumin. After oral administration of 200 mg every 24 hours for 28 days to patients with CF in a fed state, the mean (+SD) for apparent volumes of distribution was 86.0 (69.8) L. [0010] The half-life of Lumacaftor is approximately 26 hours in patients with CF. The typical apparent clearance, CL/F (CV), of Lumacaftor was estimated to be 2 38 L/hr (29.4%) for patients with CF.
[0011] Lumacaftor is not extensively metabolized in humans with the majority (51%) of Lumacaftor excreted unchanged in the feces. There was minimal elimination of Lumacaftor and its metabolites in urine (only 8.6% of total radioactivity was recovered in the urine with 0.18% as unchanged parent). ln-vitro and in vivo data indicate that Lumacaftor is mainly metabolized via oxidation and glucuronidation.
[0012] Lumacaftor has low aqueous solubility and high permeability assessed via the colorectal adenocarcinoma (Caco-2) cell system. Although pH-dependent solubility was observed, the Lumacaftor drug substance is practically insoluble in water and buffer solutions of pH 1.0 to pH 8.0. Therefore, Lumacaftor is suggested to be a BCS Class 2 (low solubility/high permeability) compound.
[0013] Since Lumacaftor is considered a BCS class II, the drug substance was jet-milled early in development to reduce the particle size and potentially improve bioavailability. Based on these studies a control on Lumacaftor particle size in the drug substance specification was established.
[0014] Various formulations have been used in the development of Lumacaftor alone and in combination which includes suspension, capsules and tablets. Comparative exposure of the different formulations of Lumacaftor was seen in single dose studies in healthy volunteers. Exposure of the suspension is lower than that seen for capsules and tablets. Early clinical studies were conducted with the co-administration of both Ivacaftor and Lumacaftor. A cross-over study (007) was conducted to evaluate the relative bioavailability of the fixed dose combination tablet as compared to the separate tablets. The tablet and FDC appear to be bioequivalent, and the only parameter that did not meet standard bioequivalence criteria is the Cmax of Ivacaftor (GLSMR [90% CI] - 1.20 [1.09, 1.33]). However, for practical purposes, this is acceptable and the PK results from tablet formulation can be considered applicable to the FDC as well.
[0015] The main medical concerns surrounding Lumacaftor is the 2-fold positive food effect when the drug is taken with a high fat meal. Elimination of the food effect would allow the administration of the drug on an empty stomach and more reliable plasma concentrations. [0016] In order to overcome the problems associated with prior conventional Lumacaftor formulations and available drug delivery systems, novel complex formulations of Lumacaftor or its salts or its derivatives thereof and complexation agents and pharmaceutically acceptable excipients were prepared. Novel complex formulations of the present invention are characterized by instantaneous redispersibility, increased apparent solubility, instantaneous dissolution, increased apparent permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.
[0017] A variety of strategies have been used to attempt to overcome these issues, see for example US7495103, US8507,534, US8653103 US8716338, US8846718, US8993600 WO2015175773, WO2009076141, WO2011127290, WO2013112804, WO2011127241, US20130085158, US20130296379, US20140221430, US20140163068, US20150196539, US20160039800, US20150140094 and WO2015073231.
BRIEF DESCRIPTION OF THE INVENTION
1. A stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Lumacaftor, or a salt or derivative thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2- oxazoline), polyvinylpyrrolidone, , poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/ propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii. optionally, pharmaceutically acceptable excipients; wherein said complex has a particle size is between 10 nm and 500 nm, and possesses one or more among the following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/mL; d) has a PAMPA permeability of at least 2xlCT6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
2. The complex according to Point 1, wherein said complex has a particle size in the range between 10 nm and 500 nm. 3. The complex according to Point 2, wherein said complex has a particle size in the range between 10 nm and 250 nm.
4. The complex according to Point 1, wherein said complex exhibits X-ray amorphous character in the solid form.
5. The complex according to Point 1, wherein said complex possesses at least two of the properties described in a) - d).
6. The complex according to Point 5, wherein said complex possesses at least three of the properties described in a)— d).
7. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, improved permeability in fasted and fed state simulation, exhibits no observable food effect which deliver full absorption and the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form.
8. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has a PAMPA permeability of at least 2x10"6 cm/s when dispersed in, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 1, preferably at least forl2 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form.
9. The complex according to Point 5, wherein said complex has an apparent solubility in water of at least 1 mg/mL and a PAMPA permeability of at least 2xl0~6 cm/s in FaSSIF and FeSSIF biorelevant media.
10. The complex according to Point 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, and has a PAMPA permeability of at least 2x10"6 cm/ s in FaSSIF and FeSSIF biorelevant media. 11. The complex according to Point 1, wherein said complexing agent is a copolymer of vinylpyrrolidone and vinylacetate.
12. The complex according to Point 1, wherein said pharmaceutically acceptable excipient is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
13. The complex according to Point 12, wherein said pharmaceutically acceptable excipient is sodium lauryl sulfate.
14. The complex according to Point 1 comprising a) Lumacaftor; b) as complexation agent a copolymer of vinylpyrrolidone and vinylacetate; c) as an excipient sodium lauryl sulfate; wherein said complex is characterized by infrared (ATR) peaks at 635 cm4, 703 cm4, 747 cm4, 837 cm4, 1021 cm4, 1165 cm4, 1231 cm , 1288 cm , 1369 cm , 1423 cm4, 1462 cm4, 1494 cm4, 1667 cm4 and 1731 cm4; and is characterized by Raman shifts at 553 cm4, 602 cm4, 635 cm4, 654 cm , 747 cm4, 841 cm4, 899 cm4, 934 cm 1, 1002 cm4, 1021 cm4, 1117 cm , 1205 cm4, 1232 cm4, 1310 cm , 1352 cm4, 1372 cm4, 1428 cm , 1444 cm , 1497 cm , 1592 cm4, 1609 cm , 1677 cm4 and 1737 cm4.
15. A complex according to either of Point 1 or Point 13 comprising a complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
16. A complex according to either of Point 1 or Point 15 comprising a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 50 weight % to about 95.0 weight % based on the total weight of the complex.
17. The complex according to Point 1, wherein said complex has an increased dissolution rate.
18. A process for the preparation of a stable complex according to Point 1, said process comprising the step of mixing a pharmaceutically acceptable solution containing Lumacaftor, and at least one complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lautyl sulfate.
19. The process according to Point 18, wherein said process is performed in a continuous flow instrument.
20. The process according to Point 19, wherein said continuous flow instrument is a micro fluidic flow instrument.
21. The process according to Point 18, wherein the pharmaceutically acceptable solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, isopropanol, n-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, or combinations thereof.
22. The process according to Point 21, wherein said pharmaceutically acceptable solvent is methanol.
23. The process according to Point 19, wherein said pharmaceutically acceptable solution and said aqueous solution are miscible with each other and the aqueous solution comprises 0.1 to 99.9% weight of the final solution.
24. A pharmaceutical composition comprising the stable complex according to Point 1 together with a pharmaceutically acceptable carrier.
25. The pharmaceutical composition according to Point 24, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
26. The pharmaceutical composition according to Point 25, wherein said composition is suitable for oral administration.
27. The pharmaceutical composition comprising the complex according to Point 26, wherein said composition comprises fast dissolving granules of the complex formulation according to Point 1.
28. The pharmaceutical composition comprising the complex according to Point 27, wherein said granules are suitable for the preparation of sachet dosage form.
29. A complex according to Point 1 for use in the treatment of CFTR mediated diseases. 30. The use according to Point 29, wherein said CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/ or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
31. A method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the complex according to Point 1 or the pharmaceutical composition according to Point 24. 32. A stable complex comprising a) 5— 40% by weight of Lumacaftor, or its salt; b) 50— 90% by weight of a copolymer of vinylpyrrolidone and vinylacetate; and c) 0.01— 50 % by weight of sodium lauryl sulfate wherein said complex has a controlled particle size in the range between 10 nm and 500 nm; and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes. 33. The complex according to Point 1, wherein said complex further comprises one or more additional active agents.
34. The complex according to Point 26, wherein said additional active agent Ivacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases. DESCRIPTION OF THE INVENTION
[0018] Disclosed herein are stable complexes comprising as active compound Lumacaftor, or salts or derivatives thereof; and at least one complexation agent.
[0019] In an embodiment, said complex further comprises at least one pharmaceutically acceptable excipient.
[0020] We have found that only the selected combinations of complexation agents and pharmaceutically acceptable excipients disclosed in the present invention result in a stable complex formulations having improved physicochemical characteristics and enhanced biological performance. [0021] The complexing agents themselves or together with the pharmaceutically acceptable excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions. The secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, π-π interactions, and hydrophobic interactions.
[0022] In an embodiment, said complex has improved physicochemical characteristics and enhanced biological performance and comprises
1. Lumacaftor, or a salt thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2- ethyl-2-oxazoline), polyvinylpyrrolidone, , poly(maleic acid/methyl vinyl ether),
(polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii. optionally, pharmaceutically acceptable excipients; wherein said complex has a particle size is between 10 nm and 500 nm, and possesses one or more among the following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/ mL; and d) has a PAMPA permeability of at least 2x10"6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
[0023] In an embodiment, said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate, polyethylene- glycols. [0024] In an embodiment, said complexation agent is copolymer of vinylpyrrolidone and vinyl acetate.
[0025] In an embodiment, said copolymer of vinylpyrrolidone and vinyl acetate has a 60:40 weight ratio of vinylpyrrolidone:vinyl acetate monomers. [0026] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium lauryl sulfate (SDS), dioctyl sodium sulfosuccinate (DSS), cetylpyridinium chloride (CPC), sodium acetate (NaOAC), sodium deoxycholate (SDC), meglumine, D-mannitol, Kollicoat-IR, citric acid and lactose.
[0027] In an embodiment, said pharmaceutically acceptable excipient is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
[0028] In an embodiment, said pharmaceutically acceptable excipient is sodium lauryl sulfate.
[0029] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
[0030] In an embodiment, said complexes have particle size between 10 nm and 500 nm. [0031] In an embodiment, said particle size is between 10 nm and 250 nm.
[0032] In an embodiment, said complex has increased dissolution rate compared to crystalline Lumacaftor.
[0033] In an embodiment, said complex is stable in solid form and in colloid solution and/or dispersion.
[0034] In an embodiment, said complex has apparent solubility in water is at least 1 mg/ mL.
[0035] In an embodiment, said complex exhibits X-ray amorphous character in the solid form.
[0036] In an embodiment, said complex has a PAMPA permeability of at least 2x10"6 cm/ s when dispersed in FaSSIF media, which does not decrease in time at least for 12 months.
[0037] In an embodiment, the variability of exposure of the complex is significantly reduced compared to the commercially available form (ORKAMBI®).
[0038] In an embodiment, said complex has no observable food effect in-vitro, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. [0039] In an embodiment said complex or its pharmaceutical composition according to the invention characterized by Raman spectrum shown in Figure 7 and ATR spectrum shown in Figure 8.
[0040] In an embodiment said complex is characterized by Raman shifts at 553 cm4, 602 cm4, 635 cm , 654 cm4, 747 cm 1, 841 cm , 899 cm4, 934 cm4, 1002 cm4, 1021 cm , 1117 cm , 1205 cm4, 1232 cm4, 1310 cm4, 1352 cm , 1372 cm4, 1428 cm4, 1444 cm , 1497 cm4, 1592 cm4, 1609 cm , 1677 cm4 and 1737 cm4.
[0041] In an embodiment said complex is characterized by infrared (ATR) peaks at 635 cm4, 703 cm4, 747 cm4 , 837 cm , 1021 cm4, 1165 cm , 1231 cm , 1288 cm , 1369 cm 1, 1423 cm 1, 1462 cm 1, 1494 cm 1, 1667 cm 1 and 1731 cm .
[0042] In an embodiment said complex comprises a) Lumacaftor; or a combination of active compounds including Lumacaftor; b) a complexing agent which is a copolymer of vinylpyrrolidone and vinyl acetate; and c) sodium lauryl sulfate as an excipient. [0043] In an embodiment, said complex comprises complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
[0044] In an embodiment, said complex comprises complexation agent which is copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate comprise 50 weight % to about 95 weight % of the total weight of the complex.
[0045] Further disclosed herein is a stable complex comprising i. 5— 40% by weight of Lumacaftor, its salt, or derivatives thereof; ii. 50— 90% by weight of copolymer of vinylpyrrolidone and vinylacetate; iii. 0.01 - 30 % by weight of sodium lauryl sulfate.
[0046] Disclosed herein is a process for the preparation of a stable complex of Lumacaftor, said process comprising the step of mixing a pharmaceutically acceptable solution containing the active agent and at least one complexing agent and optionally one or more pharmaceutically acceptable excipient with an aqueous solution containing optionally least one pharmaceutically acceptable excipient.
[0047] In an embodiment said complex is obtained via a mixing process.
[0048] In an embodiment said complex is obtained via a continuous flow mixing process.
[0049] In an embodiment said process is performed in a continuous flow instrument.
[0050] In an embodiment said continuous flow instrument is a microfluidic flow instrument.
[0051] In an embodiment, said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
[0052] In an embodiment, the pharmaceutically acceptable solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
[0053] In an embodiment, said pharmaceutically acceptable solvent is methanol.
[0054] In an embodiment, said pharmaceutically acceptable solution and said aqueous solution are miscible with each other.
[0055] In an embodiment, said aqueous solution comprises 0.1 to 99.9% weight of the final solution.
[0056] In an embodiment, said aqueous solution comprises 50 to 90% weight of the final solution.
[0057] In an embodiment, said aqueous solution comprises 50 to 80% weight of the final solution.
[0058] In an embodiment, said aqueous solution comprises 50 to 70% weight of the final solution.
[0059] In an embodiment, said aqueous solution comprises 50 to 60% weight of the final solution. [0060] In an embodiment, said aqueous solution comprises 45 to 55% weight of the final solution.
[0061] In an embodiment, said aqueous solution comprises 50 % weight of the final solution.
[0062] In an embodiment, said aqueous solution comprises 35 to 45 % weight of the final solution.
[0063] In an embodiment, said aqueous solution comprises 25 to 35 % weight of the final solution.
[0064] In an embodiment, said aqueous solution comprises 15 to 25 % weight of the final solution.
[0065] In an embodiment, said aqueous solution comprises 5 to 15 % weight of the final solution.
[0066] In an embodiment, a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
[0067] In an embodiment, said pharmaceutical composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
[0068] In an embodiment, said pharmaceutical compositions are suitable for oral administration.
[0069] In an embodiment, said pharmaceutical composition comprises fast dissolving granules.
[0070] In an embodiment, said granules are suitable for the preparation of sachet dosage form.
[0071] In an embodiment, said complexes are for use in the manufacture of a medicament for the treatment of CFTR mediated diseases.
[0072] In an embodiment, said complexes are used for the treatment of CFTR mediated diseases.
[0073] CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/ or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
[0074] In an embodiment, a method of treatment of CFTR mediated diseases comprises administration of a therapeutically effective amount of complexes or pharmaceutical compositions as described herein. [0075] In an embodiment, a method for reducing the therapeutically effective dosage of Lumacaftor compared to commercially available ORKAMBI® comprises oral administration of a pharmaceutical composition as described herein.
[0076] In an embodiment, said complexes further comprise one or more additional active agents.
[0077] In an embodiment, said additional active agent is Ivacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases. [0078] In an embodiment said complex comprises Lumacaftor; or a combination of active compounds including Lumacaftor; a complexing agent which is copolymers of vinylpyrrolidone and vinyl acetate and sodium lauryl sulfate as an excipient; said complexes characterized in that they possess at least one of the following properties: a) is instantaneously redispersible in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has apparent solubility in water of at least 1 mg/ mL; and d) has a PAMPA permeability of at least 2xl0~6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
[0079] In an embodiment, said complex possesses at least two of the properties described in a)- d).
[0080] In an embodiment, said complex possesses at least three of the properties described in a)- d).
[0081] The novel complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and eliminate the food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
[0082] The expression Lumacaftor is generally used for Lumacaftor, or its salts or its derivatives.
[0083] In an embodiment, said complexation agent is chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate.
[0084] In an embodiment, said complexation agent is a copolymer of vinylpyrrolidone and vinyl acetate and said pharmaceutically acceptable excipient is sodium lauryl sulfate, and a) is characterized by Raman shifts at 553 cm4, 602 cm4 , 635 cm4, 654 cm4, 747 cm4, 841 cm4, 899 cm , 934 cm4, 1002 cm , 1021 cm4, 1117 cm , 1205 cm , 1232 cm , 1310 cm , 1352 cm4, 1372 cm , 1428 cm , 1444 cm4, 1497 cm , 1592 cm4, 1609 cm4, 1677 cm 1 and 1737 cm4; and b) is characterized by infrared (ATR) peaks at 635 cm4, 703 cm4, 747 cm4 , 837 cm4, 1021 cm4, 1165 cm4, 1231 cm4, 1288 cm , 1369 cm4, 1423 cm , 1462 cm , 1494 cm4, 1667 cm4 and 1731 cm .
[0085] In some embodiments, the compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof. In some embodiments, active agents may include agents useful for the treatment of CFTR mediated diseases.
[0086] Another aspect of the invention is the complex formulations of the Lumacaftor with complexation agents and pharmaceutically acceptable excipients in which the complexation agents and pharmaceutically acceptable excipients preferably are associated or interacted with the Lumacaftor, such as the results of a mixing process or a continuous flow mixing process. In some embodiment, the structure of the complex Lumacaftor formulation is different from the core-shell type milled particle, precipitated encapsulated particles, micelles and solid dispersions.
[0087] The pharmaceutical composition of the invention can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination of (a), (b), and (c).
[0088] The compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
[0089] In an embodiment, the dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized. [0090] Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders (sachet), and granules. In such solid dosage forms, the complex formulation of Lumacaftor is admixed with at least one of the following: one or more inert excipients (or carriers): (a) fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, etythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide; (b) sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid; (c) binders, such as cellulose derivatives, acrylic acid derivatives, alginates, gelatin, polyvinylpyrrolidone, starch derivatives, dextrose, dextrates, dextrin, maltose, maltodextrin; (d) disintegrating agents, such as crospovidon, effervescent compositions, croscarmellose sodium and other cellulose derivatives, sodium starch glycolate and other starch derivatives, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders, such as acrylates, cellulose derivatives, paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as polysorbates, cetyl alcohol and glycerol monostearate; (h) lubricants such as talc, stearic acid and its derivatives, solid polyethylene glycols, sodium lauryl sulfate, glyceryl behenate, medium-chain triglycerides or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
[0091] In an embodiment, the dosage form of the invention is a liquid dispersible granules in a sachet form.
[0092] In an embodiment, said liquid dispersible granules comprise the complex formulation of Lumacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide.
[0093] In an embodiment, said liquid dispersible granules comprise the complex formulation of Lumacaftor of the present invention together with pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid.
[0094] Further disclosed herein is a liquid dispersible granules comprising a) 25—95 % stable complex formulation of Lumacaftor of the present invention;
b) 5 -75 % fillers or extenders;
c) 0.5 -25 % binders;
d) 0.1—5 % sweetening, flavoring, aromatizing and perfuming agents; wherein said liquid dispersible granules disperses within 3 min in liquid; and wherein said liquid dispersible granules obtained by wet or dry processes. [0095] In an embodiment, said dispersion time is between 0.1 min and 10 min.
[0096] In an embodiment, said dispersion time is between 0.1 min and 5 min.
[0097] In an embodiment, said dispersion time is between 0.1 min and 3 min.
[0098] In an embodiment, said dispersion time is between 0.1 min and 1 min.
[0099] In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Lumacaftor formulations is less than 1.25, more preferably 1.00-1.18
[00100] In an embodiment, Hausner-ratio of the said liquid dispersible granules of complex Lumacaftor formulations is between 1.00 and 1.18.
[00101] In an embodiment, the particle size (D(90)) of said solid aggregates of complex Lumacaftor formulations is less than 2000 micrometers. [00102] In an embodiment, 60-99 % of the said solid aggregates of complex Lumacaftor formulations are in the size range of 160-1200 micrometers
[00103] In an embodiment, said liquid is water, saliva, other physiologically or biologically acceptable fluid.
[00104] In an embodiment, the dosage form is chosen from a tablet and a capsule. [00105] Advantages of the complex Lumacaftor formulation of the invention include, but are not limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased apparent solubility and permeability compared to the conventional Lumacaftor formulation in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect, (5) good processability. [00106] In an embodiment, said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, improved permeability in fasted and fed state simulation, exhibits no observable food effect which deliver full absorption and the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form. [00107] In an embodiment, said complex possesses instantaneous redispersibility, has a
PAMPA permeability of at least 2x10"6 cm/s when dispersed in, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form. [00108] Beneficial features of the present invention are as follows: the good/instantaneous redispersibility of solid complex formulations of Lumacaftor in water, biologically relevant media, e.g. physiological saline solution, pH=2.5 HC1 solution, FaSSIF and FeSSIF media and gastro intestinal fluids and adequate stability in colloid solutions and/or dispersion in the therapeutic time window. [00109] In an embodiment, the complex Lumacaftor formulation of the present invention has increased apparent solubility and permeability. In some embodiments, the apparent solubility and permeability of the complex Lumacaftor formulation is at least 1 mg/mL and 2xl0~6 cm/s in FaSSIF and FeSSIF biorelevant media, respectively.
[00110] In an embodiment, said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, and has a PAMPA permeability of at least 2x10"6 cm/ s in FaSSIF and FeSSIF biorelevant media.
[00111] In another embodiment, the complex Lumacaftor formulations of the present invention have an enhanced pharmacokinetic performance with improved solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect. BRIEF DESCRIPTION OF THE DRAWINGS
[00112]The accompanying figures, which are incorporated and form part of the specification, merely illustrate certain embodiments of the present invention and should not be construed as limiting the invention. They are meant to serve to explain specific modes of the present invention to those skilled in the art.
Figure 1. shows redispersibility of complex Lumacaftor compositions in ultrapurified water.
Figure 2. shows redispersibility and PAMPA permeability of complex Lumacaftor compositions in purified water.
Figure 3. shows PAMPA permeability of complex Lumacaftor formulations containing vinylpyrrolidone and vinylacetate copolymer and sodium lauryl sulfate in different ratios.
Figure 4. shows optimization of production parameters.
Figure 5. shows Lumacaftor dissolution from crystalline Lumacaftor and complex Lumacaftor formulation.
Figure 6. shows PAMPA permeabilities of Lumacaftor formulations measured at different time points.
Figure 7. shows SEM photo of complex Lumacaftor formulation.
Figure 8. shows Raman spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Kollidon VA64 (E), SDS (F).
Figure 9. shows ATR spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Kollidon VA64 (E), SDS (F).
Figure 10. shows XRD diffractograms of crystalline Lumacaftor and complex Lumacaftor formulation.
Figurell. shows apparent solubility of Lumacaftor formulations. Figurel2. shows PAMPA permeability of Lumacaftor formulations.
EXAMPLES [00113] Specific embodiments of the present invention will further be demonstrated by the following examples. It should be understood that these examples are disclosed only by way of illustration and should not be construed as limiting the scope of the present invention.
Selection of complex Lumacaftor formulations with improved material properties [00114] Several complexation agents and pharmaceutically acceptable excipients and their combinations were tested in order to select the formulations having instantaneous redispersibility as shown in Figure 1.
[00115] Examples that displayed an acceptable level of redispersibility were selected for further analysis. [001 16] PAMPA permeability of the selected formulations was measured in order to select complex Lumacaftor formulation having the best in-vitro performance (Figure 2) . PAMPA permeability measurements were performed as described by M. Kansi et al. (Journal of medicinal chemistry, 41, (1998) pp 1007) with modifications based on S. Bendels et al (Pharmaceutical research, 23 (2006) pp 2525) . Permeability was measured in a 96-well plate assay across an artificial membrane composed of dodecane with 20% soy lecithin supported by a PVDF membrane (Millipore, USA) . The receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1 % sodium dodecyl sulfate. The assay was performed at room temperature; incubation time was 4 hours in ultrapurified water, FaSSIF and FeSSIF, respectively. The concentration in the receiver compartment was determined by UV-VIS spectrophotometry (VWR UV-3100PC Scanning Spectrophotometer).
[00117] Copolymer of vinylpyrrolidone and vinylacetate was selected as complexing agents and sodium lauryl sulfate was selected as pharmaceutically acceptable excipient in order to prepare complex Lumacaftor formulations having improved material characteristics.
[00118]The ratio of the selected complexation agent and pharmaceutically acceptable excipient was optimized. Solid complexes of Lumacaftor were prepared by using different ratios of complexation agent and pharmaceutically acceptable excipient. PAMPA permeability measurements were used to select the best performing complex formulation (Figure 3) . The optimal ratio of the copolymer of vinylpyrrolidone and vinylacetate : sodium lauryl sulfate: Lumacaftor (API) was found to be 9:1.2:2. Production of complex Lumacaftor formulations [00119] A solution mixture of Lumacaftor complex formulation was prepared by continuous flow mixing approach. 20 mL Solution 1 was prepared by dissolving 40 mg Lumacaftor and 180 mg copolymer of vinylpyrrolidone and vinylacetate in 20 mL methanol. The prepared Solution 1 was mixed with Solution 2 containing 24 mg sodium lauryl sulfate in 80 mL water at 1:4 volume ratio in order to produce complex Lumacaftor formulation with different flow rates. The solution mixture of the complex Lumacaftor formulation was produced at atmospheric pressure and ambient temperature. The appearance and the particle size of the produced colloid solution were monitored. Based on the physical appearance and particle size of the produced complex Lumacaftor formulation in colloid solution, the best composition was selected for further experiments (Figure 4). The produced solution mixture was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump. Spray-drying was also applicable to produce solid powder from the solution mixture of complex Lumacaftor formulation.
[00120] In order to make the production process industrially feasible process intensification was performed by increasing the concentrations of the starting solutions. A colloid solution of complex Lumacaftor formulation of the present invention was prepared by mixing process.
Solution 1 containing 200 mg Ivacaftor and 900 mg copolymer of vinylpyrrolidone and vinylacetate in 20 mL methanol was mixed with aqueous Solution 2 containing 120 mg sodium lauryl sulfate in 80 mL ultrapurified water at 1:4 volume ratio in order to produce complex Lumacaftor formulation. The produced solution mixture was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump.
Spray-drying was also applicable to produce solid powder from the solution mixture of complex
Lumacaftor formulation.
Preparation of liquid dispersible granules comprising complex Lumacaftor formulation [00121]Liquid dispersible granules comprising the complex Lumacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
[00122]Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Lumacaftor into compacts and breaking of the compacts into granules with appropriate mesh size. The obtained granules can be mixed with pharmaceutically acceptable excipients.
[00123]Dry granulation technique can be also applied on the powder blend of complex Lumacaftor formulations. Powder blend consists of the powder formulation of complex Lumacaftor and pharmaceutically acceptable excipients and prepared by mixing of powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
[00124]Wet granulation process covers the moisturizing of the powder formulations of complex Lumacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and mixing it with the powder formulations of complex Lumacaftor (indirect granulation). The particle size of the granules can be controlled by physical impact before and after the drying step.
[00125]Liquid dispersible granules of complex Lumacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Lumacaftor powder blend using 0.5 ton load. The powder blend comprised of the solid formulation of the complex of Lumacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents. The height of the compact was found to be optimal between 0.8-1.0 mm. The compacts were broken up by physical impact to form granulates. The particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160- 800 micrometers particle size. The Hausner-ratio of the granule was between 1.00 and 1.18 and the Carr's index was≤ 15.
Comparative solubility tests
[00126]The apparent solubility of complex Lumacaftor formulation of the present invention was measured by UV-VIS spectroscopy at room temperature. The solid complex Lumacaftor formulations were dispersed in ultrapurified in 1, 10 and 20 mg/mL Lumacaftor equivalent concentration range. The resulting solutions were filtered by 100 nm disposable syringe filter. The Lumacaftor content in the filtrate was measured by UV-Vis spectrophotometry and the apparent solubility was calculated. The filtrate may contain Lumacaftor complex particles which could not be filtrated out using 100 nm pore size filter.
[00127]The apparent solubility of complex Lumacaftor formulation of the present invention was 0.950, 9.839 and 14.913 mg/mL, when 1, 10 and 20 mg/mL Lumacaftor equivalent formulations were dispersed in ultrapurified water, respectively. The apparent solubility of unformulated crystalline Lumacaftor was found to be 0.032 mg/mL. [00128] Solubility of complex Lumacaftor formula was 1 mg/mL. Comparative dissolution tests
[00129] Comparative dissolution tests were performed by dispersing 1 mg/mL Lumacaftor equivalent complex Lumacaftor formulation and crystalline Lumacaftor in 15 mL FaSSIF and FeSSIF media under stirring. The dissolved amount was measured with HPLC after filtration with 220 nm pore size filter at different time points. Dissolution of Lumacaftor from the complex formulation was instantaneous, while the dissolution of crystalline Lumacaftor was slower (Figure 5). Within 10 minutes the Lumacaftor dissolution from the complex formulation of the present invention was almost complete (100%), while it was below 1% from the crystalline Lumacaftor. Comparative in-vitro PAMPA assays
[00130] Since Lumacaftor should be administered with food in order to improve its biological performance, PAMPA permeabilities of amorphous Lumacaftor, crystalline Lumacaftor and complex Lumacaftor formulation were measured and compared in simulated fasted state. PAMPA permeability of amorphous Lumacaftor, crystalline Lumacaftor and complex Lumacaftor formulation was 1.1798xl0~6 cm/s, 0.53053xl0~6 cm/s and 3.9615x10 6 cm/ s, respectively.
Stability of the complex Lumacaftor formulation in solid form
[00131] PAMPA permeabilities of the solid complex Lumacaftor formulations were used to monitor the physical stability of the formulations. PAMPA permeability was measured in FaSSIF biorelevant media and after storage at different conditions. 1 month storage at RT or 40 °C 75% relative humidity showed no significant decrease in the measured PAMPA permeability (Figure 6).
Structural analysis
[00132] Morphology of complex Lumacaftor formulation was investigated using FEI Quanta 3D scanning electron microscope. Complex Lumacaftor formulation of the present invention comprises spherical particles in the size range of less than 100 nm (Figure 7).
[00133] Structural analysis was performed by using Vertex 70 FT-IR with ATR and HOR1BA JobmYvon LabRAM HR UV-VTS-NIR instruments. [00134] Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic Raman shifts at 553 cm4, 602 cm4, 635 cm4, 654 cm4, 747 cm4, 841 cm4, 899 cm4, 934 cm4, 1002 cm4, 1021 cm4, 1117 cm , 1205 cm4, 1232 cm4, 1310 cm4, 1352 cm , 1372 cm4, 1428 cm , 1444 cm4, 1497 cm , 1592 cm , 1609 cm 1, 1677 cm4 and 1737 cm 1 shown in Figure 8 .
[00135] Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic Raman shifts at 553 cm4, 654 cm4, 747 cm4, 841 cm4, 899 cm4, 1117 cm , 1205 cm , 1310 cm4, 1372 cm , 1428 cm4, 1677 cm 1 and 1737 cm .
[00136] Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic infrared (ATR) peaks at 635 cm4, 703 cm4, 747 cm4, 837 cm4, 1021 cm4, 1165 cm , 1231 cm4, 1288 cm , 1369 cm4, 1423 cm , 1462 cm , 1494 cm4, 1667 cm 1 and 1731 cm4 shown in Figure 9. 37] Complex Lumacaftor formulation or its pharmaceutical composition is characterized by characteristic infrared (ATR) peaks at 703 cm4, 837 cm4, 1231 cm4, 1369 cm4 and 1667 cm4. [00138]The structure of the complex Lumacaftor formulation of the present invention was investigated by powder X-ray diffraction (XRD) analysis (Philips PW1050/1870 RTG powder- diffractometer). The measurements showed that the Lumacaftor in the complex formulations was XRD amorphous (Figure 10) . Characteristic reflections on the diffractograms of complex Lumacaftor formulation at 43 and 44 2Theta could be attributed to sample holder.
[00139] Based on in-vitro data which shows fast and full dissolution and increased permeability in fasted and fed state simulation it is expected that the complex Lumacaftor formulation delivers full absorption and the elimination of the food effect.
Comparative formulation studies [00140] Crystalline Lumacaftor was ball milled in the absence of complexation agent (Kollidon VA64) and pharmaceutically acceptable excipient (SDS) and in the presence of them. Ball milling parameters were the following:
Speed: 500 rpm
Milling time: 1 hour
Number of the balls: 25 pes with 10 mm diameter Milling vessel's material: Si2N3
Quantity of the milled samples: 100 mg API equivalent mass in 12 mL Milli-Q water
After the milling the vessel was washed out with 5 mL Milli-Q water. The product was frozen on salted ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump. The material and in-vitro properties of the resulted formulations were compared to the complex Lumacaftor formulation of the present invention.
[00141]Particle size of the formulations was measured in reconstituted dispersion/solution. It was d(90) = 782 nm and d(90) =282 nm for the ball milled Lumacaftor with Kollidon VA64 and SDS and complex Lumacaftor formulation, respectively. Ball milled crystalline Lumacaftor was hardly redispersible in purified water resulting in a suspension with visible particles, the particle size could not be determined.
[00142] Apparent solubility of complex Lumacaftor formulation was 14.913 mg/mL when 20 mg Lumacaftor equivalent formulation was redispersed (Figure 11).
[00143]PAMPA permeability of the formulations was measured in FaSSIF biorelevant media and compared. PAMPA permeability of the complex Lumacaftor formulation was 4.651x10 6 cm/s, while it was 0.288xl0~6 cm/s for the ball milled crystalline Lumacaftor (Figure 12).
[00144] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

WHAT IS CLAIMED IS
1. A stable complex with improved physicochemical characteristics and enhanced biological performance comprising i. Lumacaftor, or a salt or derivative thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymer of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2- oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/ propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and iii. optionally, pharmaceutically acceptable excipients; wherein said complex has a particle size is between 10 nm and 500 nm, and possesses one or more among the following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/mL; d) has a PAMPA permeability of at least 2xl0~6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month.
2. The complex as recited in Claim 1, wherein said complex has a particle size in the range between 10 nm and 500 nm.
3. The complex as recited in Claim 2, wherein said complex has a particle size in the range between 10 nm and 250 nm.
4. The complex as recited in Claim 1, wherein said complex exhibits X-ray amorphous character in the solid form.
5. The complex as recited in Claim 1, wherein said complex possesses at least two of the properties described in a)— d).
6. The complex as recited in Claim 5, wherein said complex possesses at least three of the properties described in a)— d).
7. The complex as recited in Claim 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/mL, improved permeability in fasted and fed state simulation, exhibits no observable food effect which deliver full absorption and the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form.
8. The complex as recited in Claim 6, wherein said complex possesses instantaneous redispersibility, has a PAMPA permeability of at least 2xlCT6 cm/s when dispersed in, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 12 month, exhibits no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Lumacaftor in solution form.
9. The complex as recited in Claim 5, wherein said complex has an apparent solubility in water of at least 1 mg/mL and a PAMPA permeability of at least 2xlCT6 cm/s in FaSSIF and FeSSIF biorelevant media.
10. The complex as recited in Claim 6, wherein said complex possesses instantaneous redispersibility, has an apparent solubility in water of at least 1 mg/ mL, and has a PAMPA permeability of at least 2x1 CT6 cm/s in FaSSIF and FeSSIF biorelevant media.
11. The complex as recited in Claim 1, wherein said complexing agent is a copolymer of vinylpyrrolidone and vinylacetate.
12. The complex as recited in Claim 1, wherein said pharmaceutically acceptable excipient is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
13. The complex as recited in Claim 12, wherein said pharmaceutically acceptable excipient is sodium lauryl sulfate.
14. The complex as recited in Claim 1 comprising a) Lumacaftor; b) a complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate; c) an excipient which is sodium lauryl sulfate; wherein said complex is characterized by infrared (ATR) peaks at 635 cm4, 703 cm4, 747 cm4, 837 cm4, 1021 cm4, 1165 cm4, 1231 cm , 1288 cm , 1369 cm , 1423 cm4, 1462 cm4, 1494 cm4, 1667 cm4 and 1731 cm4; and is characterized by Raman shifts at 553 cm4, 602 cm4, 635 cm4, 654 cm , 747 cm4, 841 cm4, 899 cm4, 934 cm 1, 1002 cm4, 1021 cm4, 1117 cm , 1205 cm4, 1232 cm4, 1310 cm , 1352 cm4, 1372 cm4, 1428 cm , 1444 cm , 1497 cm , 1592 cm4, 1609 cm , 1677 cm4 and 1737 cm4.
15. A complex according to either of Claims 1 or 13 comprising a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
16. A complex according to either of Claims 1 or 15 comprising a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 50 weight % to about 95.0 weight % based on the total weight of the complex.
17. The complex as recited in Claim 1, wherein said complex has an increased dissolution rate.
18. A process for the preparation of a stable complex as recited in Claim 1, said process comprising the step of mixing a pharmaceutically acceptable solution containing Lumacaftor, and at least one complexing agent which is copolymer of vinylpyrrolidone and vinylacetate with an aqueous solution containing at least one pharmaceutically accepted excipient selected from the group of sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
19. The process as recited in Claim 18, wherein said process is performed in a continuous flow instrument.
20. The process as recited in Claim 19, wherein said continuous flow instrument is a micro fluidic flow instrument.
21. The process as recited in Claim 18, wherein the pharmaceutically acceptable solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, isopropanol, n- propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, or combinations thereof.
22. The process as recited in Claim 21, wherein said pharmaceutically acceptable solvent is methanol.
23. The process as recited in Claim 19, wherein said pharmaceutically acceptable solution and said aqueous solution are miscible with each other and the aqueous solution comprises 0.1 to 99.9% weight of the final solution.
24. A pharmaceutical composition comprising the stable complex as recited in Claim 1 together with a pharmaceutically acceptable carrier.
25. The pharmaceutical composition as recited in Claim 24, wherein said composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
26. The pharmaceutical composition as recited in Claim 25, wherein said composition is suitable for oral administration.
27. The pharmaceutical composition comprising the complex according to Claim 26, wherein said composition comprises fast dissolving granules of the complex formulation according to Claim 1.
28. The pharmaceutical composition comprising the complex according to Claim 27, wherein said granules are suitable for the preparation of sachet dosage form.
29. A complex according to Claims 1 for use in the treatment of CFTR mediated diseases.
30. The use of claim 29, wherein said CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-
Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a term for inherited disorders of the structure and/ or function of cilia, including PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
31. A method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the complex according to Claims 1 or the pharmaceutical composition according to Claim 24.
32. A stable complex comprising a) 5— 40% by weight of Lumacaftor, its salt, or derivatives thereof; b) 50— 90% by weight of a copolymer of vinylpyrrolidone and vinylacetate; and c) 0.01— 50 % by weight of sodium lauryl sulfate wherein said complex has a controlled particle size in the range between 10 nm and 500 nm; and wherein said complex is not obtained via a milling process, high pressure homogenization process, encapsulation process or solid dispersion processes.
33. The complex as recited in Claim 1, wherein said complex further comprises one or more additional active agents.
34. The complex as recited in Claim 26, wherein said additional active agent Ivacaftor, Tezacaftor or chosen from agents used for the treatment of CFTR mediated diseases.
PCT/IB2017/052372 2016-04-25 2017-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them Ceased WO2017187338A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP17731268.3A EP3448385A1 (en) 2016-04-25 2017-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CA3021941A CA3021941A1 (en) 2016-04-25 2017-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
AU2017256182A AU2017256182A1 (en) 2016-04-25 2017-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN201780039665.5A CN109475547A (en) 2016-04-25 2017-04-25 Compounds of rumacator and its salts and derivatives, methods for its preparation and pharmaceutical compositions containing them
JP2018555731A JP2019514897A (en) 2016-04-25 2017-04-25 Complexes of lumacafitol and its salts and derivatives, processes for their preparation and pharmaceutical compositions containing them
IL262490A IL262490A (en) 2016-04-25 2018-10-21 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1600269A HUP1600269A2 (en) 2016-04-25 2016-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600269 2016-04-25

Publications (2)

Publication Number Publication Date
WO2017187338A1 true WO2017187338A1 (en) 2017-11-02
WO2017187338A4 WO2017187338A4 (en) 2017-12-28

Family

ID=89992147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/052372 Ceased WO2017187338A1 (en) 2016-04-25 2017-04-25 Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Country Status (8)

Country Link
EP (1) EP3448385A1 (en)
JP (1) JP2019514897A (en)
CN (1) CN109475547A (en)
AU (1) AU2017256182A1 (en)
CA (1) CA3021941A1 (en)
HU (1) HUP1600269A2 (en)
IL (1) IL262490A (en)
WO (1) WO2017187338A1 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2009076141A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8507534B2 (en) 2007-12-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20140163068A1 (en) 2012-11-02 2014-06-12 Vertex Pharmaceuticals Incorporated Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
US8993600B2 (en) 2005-11-08 2015-03-31 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20150132388A1 (en) * 2013-11-12 2015-05-14 Druggability Technologies Holdings Limited Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015071841A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
WO2015071837A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015121836A1 (en) * 2014-02-14 2015-08-20 Druggability Technologies Ip Holdco Limited Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311180A (en) * 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamode and uses thereof

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8993600B2 (en) 2005-11-08 2015-03-31 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8846718B2 (en) 2007-12-07 2014-09-30 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8507534B2 (en) 2007-12-07 2013-08-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2009076141A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8653103B2 (en) 2007-12-07 2014-02-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20160039800A1 (en) 2008-09-29 2016-02-11 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20130296379A1 (en) 2010-04-07 2013-11-07 Vertex Pharmaceuticals Incorporated Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20140221430A1 (en) 2010-04-07 2014-08-07 Vertex Pharmaceuticals Incorporated Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid
US20150140094A1 (en) 2010-04-07 2015-05-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
US20130085158A1 (en) 2010-04-07 2013-04-04 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20150196539A1 (en) 2010-04-07 2015-07-16 Vertex Phamraceuticals Incorporated Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)Cyclopropanecarboxamido)-3-Methylpyridin-2-yl)Benzoic Acid
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20140163068A1 (en) 2012-11-02 2014-06-12 Vertex Pharmaceuticals Incorporated Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
WO2015073231A1 (en) 2013-11-12 2015-05-21 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
WO2015071837A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015071841A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20150132388A1 (en) * 2013-11-12 2015-05-14 Druggability Technologies Holdings Limited Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015121836A1 (en) * 2014-02-14 2015-08-20 Druggability Technologies Ip Holdco Limited Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURTIS J ROSEBRAUGH: "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORKAMBI safely and effectively. See full prescribing information for ORKAMBI", 1 July 2015 (2015-07-01), XP055400867, Retrieved from the Internet <URL:https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf> [retrieved on 20170824] *
M. KANSI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 1007
RASK MALTE BILLE ET AL: "Influence of PVP/VA copolymer composition on drug-polymer solubility", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, 28 January 2016 (2016-01-28), pages 10 - 17, XP029449537, ISSN: 0928-0987, DOI: 10.1016/J.EJPS.2016.01.026 *
S. BENDELS ET AL., PHARMACEUTICAL RESEARCH, vol. 23, 2006, pages 2525

Also Published As

Publication number Publication date
JP2019514897A (en) 2019-06-06
CA3021941A1 (en) 2017-11-02
HUP1600269A2 (en) 2017-10-30
WO2017187338A4 (en) 2017-12-28
AU2017256182A1 (en) 2018-12-13
IL262490A (en) 2018-12-31
EP3448385A1 (en) 2019-03-06
CN109475547A (en) 2019-03-15

Similar Documents

Publication Publication Date Title
US10675277B2 (en) Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ES2857152T3 (en) Pharmaceutical composition and administrations thereof
US20200022969A1 (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US20210228489A1 (en) Compositions for treating cystic fibrosis
US20150010628A1 (en) Pharmaceutical composition and administrations thereof
KR101953270B1 (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
US10688110B2 (en) Complexes of Celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20150132388A1 (en) Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3448384A1 (en) Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US20190388408A1 (en) Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3548029A1 (en) Pharmaceutical formulation containing tadalafil
WO2017187338A1 (en) Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2017187336A1 (en) Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015199115A1 (en) Pharmaceutical composition for oral administration
US20250248981A1 (en) Compositions for the treatment of cftr-mediated diseases
CN106913542B (en) Prasugrel tablet and preparation method thereof
JP2024094310A (en) Pharmaceutical composition comprising solid dispersion of apalutamide
JP2004307377A (en) Itraconazole composition having improved absorbability and used for oral administration

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3021941

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018555731

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017731268

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17731268

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017731268

Country of ref document: EP

Effective date: 20181126

ENP Entry into the national phase

Ref document number: 2017256182

Country of ref document: AU

Date of ref document: 20170425

Kind code of ref document: A